Paul Kamudoni
Merck & Co.
Quality of lifeCronbach's alphaPhysical therapyObservational studyLongitudinal studyReliability (statistics)Construct validityContent validityMedicineCohort
Publications 1
#1Paul Kamudoni (MSD: Merck & Co.)
#2Jeffrey Johns (Cardiff University)H-Index: 3
Last. Kevin N. Alschuler (UW: University of Washington)H-Index: 21
view all 13 authors...
Abstract null null Background null Fatigue is one of the most common and the single most disabling symptom of multiple sclerosis (MS). However, there is a lack of consensus on the most appropriate fatigue measures in clinical practice and research, based upon rigorously validated, generalizable, and publicly available instruments. The objective of this research was to generate additional evidence regarding the validity and applicability of the PROMIS SF v1.0 – Fatigue (MS) 8a, including content ...